亚盛医药-JPM-20240110 .pdf

《亚盛医药-JPM-20240110 .pdf》由会员分享，可在线阅读，更多相关《亚盛医药-JPM-20240110 .pdf（39页珍藏版）》请在三个皮匠报告上搜索。

1、J.P.Morgan Healthcare Conference 2024Patient-Centric Innovation|Global Breakthrough Therapies(Ticker:6855.HK)January 10,2024Dr.Dajun Yang,Chairman&CEO2Ascentage PharmaDisclaimer3Ascentage PharmaAscentage PharmaPatient-Centric Innovation|Global Breakthrough TherapiesMISSIONTo address global unmet med

2、ical needsVISIONTo become a global leading integrated biopharmaceutical companyVALUEPatients first;Science-based;Data-driven34Ascentage Pharma1.24 million6%Global blood cancer annual incidence of all cancer casesUS$90bn30%Global hematological malignancy treatment market(2028E)of total cancer therapy

3、 marketSource:American Cancer Society,Mordor Intelligence,Leukemia and Lymphoma Society,Company forecast and dataBlood cancer market at a glanceWell-positioned to capture the US$10bn+global blood cancer market opportunitiesCML$7.2bnALL$2.3 bnCLL$13.2 bnAML$3.1 bnMM$25.7 bnMDS$3.3 bnAscentage PharmaW

4、ith proper treatments keeping the disease at bay,patients with certain blood cancers such as chronic myeloid leukemia(CML)can expect to have a normal length of life45Ascentage PharmaAscentage Pharma pipeline summaryCompoundsTargetIndicationsPreclinicalPhase IPhase IIRegistration TrialNDA ApprovalTri

5、al RegionRights RegionOlverembatinib(HQP1351)BCR-ABL/KITResistant CMLTN Ph+ALLGISTResistant CML，Ph+ALLLisaftoclax(APG-2575)Bcl-2 SelectiveBTKi treated CLL/SLL(Global-FDA)r/r CLL/SLL(China)TN CLL/SLL(Global)WMAMLMDSMMT-PLLMCLER+/HER2-BC and Solid TumorsArizomadlin(APG-115)MDM2-p53Melanoma and Solid T

6、umorsACCAML,MDSAPG-1387IAP/XIAPSolid tumors(IO Combo)PDAC+ChemoCHBPelcitoclax(APG-1252)Bcl-2/Bcl-xLNSCLC+TKISCLC+ChemoNETNHLAPG-2449FAK/ALK/ROS1NSCLC/Solid tumorsAPG-5918EED SelectiveTumors/HemoglobinopathyAPG-265PROTACs MDM2 TumorsUBX1967/1325Bcl FamilyDMESource:Company data6Ascentage Pharma2023 ac